12 articles
Johnson & Johnson announced positive early-stage trial results for its experimental prostate cancer drug JNJ-6143, acquired through a $3.05 billion Halda Therapeutics deal. The drug demonstrated signi
Smith & Nephew and Johnson & Johnson abandoned merger talks for the latter's orthopaedics division due to disagreements over the CEO position. The proposed $22 billion deal collapsed after Smith & Nep
Asian stocks advanced on expectations of fewer Fed rate hikes, with oil prices rising and Johnson & Johnson reporting mixed results in its medical technology division.
Johnson & Johnson reported third-quarter profits exceeding expectations, driven by strong Tremfya sales, though geopolitical tensions in the Middle East hindered medical device revenue growth. The com
Apollo Global Management is reportedly in talks to acquire Johnson & Johnson's orthopedics unit, DePuy Synthes, in a deal valued near $20 billion. The unit, which generated $9.3 billion in sales last
Johnson & Johnson agreed to a $5.5 billion settlement resolving nearly 70,000 lawsuits alleging its talc products caused ovarian cancer. The company denies the claims and switched to cornstarch-based
Johnson & Johnson beat Q2 sales and profit estimates, driven by strong growth in key drugs like Tremfya and Darzalex. It raised its full-year forecast despite challenges in its medical technology unit
Johnson & Johnson agreed to acquire Firefly Bio for $1 billion to bolster its oncology pipeline with Firefly's Firelink platform. The technology targets KRAS-driven cancers, offering potential treatme
A Los Angeles jury ruled in favor of Johnson & Johnson in a lawsuit claiming its talc products caused ovarian cancer. J&J faces over 67,000 similar suits but halted U.S. talc-based baby powder sales i
Johnson & Johnson will market four prescription drugs on the Trump administration's TrumpRx platform under an agreement to reduce prices and secure tariff exemptions. Specific medications remain undis
Johnson & Johnson beat first-quarter earnings estimates with $24.1 billion revenue, raising its full-year forecast despite a 60% drop in Stelara sales due to biosimilar competition. Growth in cancer a
EpiBiologics secured $107 million Series B funding backed by Google and Johnson & Johnson to advance protein-degrading drug candidates into human trials based on UCSF research.
ChemBrief